646071-31-0

Basic information

• Product Name: Hydrazinecarboxylic acid, 2-cyclopentyl-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Hydrazinecarboxylic acid, 2-cyclopentyl-, 1,1-dimethylethyl ester (9CI);N'-Cyclopentyl-hydrazinecarboxylic acid tert-butyl ester;2-cyclopentylHydrazinecarboxylic acid 1,1-dimethylethyl ester;tert-butyl2-cyclopentylhydrazine-1-carboxylate
• CAS NO: 646071-31-0
• Molecular Formula: C₁₀H₂₀N₂O₂
• Molecular Weight: 200.278
• Product Categories: N-BOC
• Mol File: 646071-31-0.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Hydrazinecarboxylic acid, 2-cyclopentyl-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Hydrazinecarboxylic acid, 2-cyclopentyl-, 1,1-dimethylethyl ester (9CI)(646071-31-0)
• EPA Substance Registry System: Hydrazinecarboxylic acid, 2-cyclopentyl-, 1,1-dimethylethyl ester (9CI)(646071-31-0)

Safety Data

• Hazardous Substances Data: 646071-31-0(Hazardous Substances Data)

Upstream product

• 120-92-3 cyclopentanone 
• 870-46-2 t-butoxycarbonylhydrazine 
• 79201-39-1 tert-butyl 2-cyclopentylidenehydrazine carboxylate 

Downstream Products

• 24214-72-0 cyclopentylhydrazine hydrochloride 
• 30241-37-3 1-cyclopentyl-3-methyl-1H-pyrazol-5-amine 
• 1055924-99-6 N'-(2-cyano-9-methyl-9H-purin-6-yl)-N'-cyclopentyl-4-({4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperidinyl}methyl)benzohydrazide trifluoroacetate 
• 1055925-94-4 N'-{2-cyano-9-[2-(dimethylamino)ethyl]-9H-purin-6-yl}-N'-cyclopentyl-6-{4-[(4-methyl-1-piperazinyl)methyl]phenyl}-2-pyridinecarbohydrazide trifluoroacetate 
• 1055924-97-4 N'-(2-cyano-9-methyl-9H-purin-6-yI)-N'-cyclopentyl-4-({4-[(1-methyl-4-piperidinyl)methyl]-1-piperazinyl}methyl)benzohydrazide trifluoroacetate 
• 1055924-93-0 N'-(2-cyano-9-methyl-9H-purin-6-yI)-N'-cyclopentyl-4-{[4-(4-methyl-1-piperazinyl)-1-piperidinyl]methyl}benzohydrazide trifluoroacetate 
• 1055925-51-3 N'-(2-cyano-9-methyl-9H-purin-6-yI)-N'-cyclopentyl-5-{4-[(4-methyl-1-piperazinyl)methyl]phenyl}-3-pyridinecarbohydrazide trifluoroacetate 
• 1055925-53-5 N'-(2-cyano-9-methyl-9H-purin-6-yI)-N'-cyclopentyl-6-{4-[(4-methyl-1-piperazinyl)methyl]phenyl}-2-pyridinecarbohydrazide trifluoroacetate 
• 1055925-87-5 N'-{2-cyano-9-[2-(dimethylamino)ethyl]-9H-purin-6-yl}-N'-cyclopentyl-4-[(4-methyl-1-piperazinyl)methyl]benzohydrazide trifluoroacetate 
• 1055925-04-6 N'-(2-cyano-9-methyl-9H-purin-6-yI)-N'-cyclopentyl-4-{[3-(1-pyrrolidinyl)-1-azetidinyl]methyl}benzohydrazide trifluoroacetate 
• 1055926-08-3 N'-(2-cyano-9-methyl-9H-purin-6-yl)-N'-cyclopentyl-4-[(4-methyl-1-piperazinyl)methyl]benzohydrazide trifluoroacetate 
• 1055925-62-6 N'-(2-cyano-9-methyl-9H-purin-6-yl)-N'-cyclopentyl-4-(4-methyl-1-piperazinyl)benzohydrazide trifluoroacetate 
• 1055925-66-0 N'-(2-cyano-9-methyl-9H-purin-6-yI)-N'-cyclopentyl-3-(4-methyl-1-piperazinyl)benzohydrazide trifluoroacetate 
• 1055925-93-3 N'-{2-cyano-9-[2-(dimethylamino)ethyl]-9H-purin-6-yl}-N'-cyclopentyl-6-{4-[(4-methyl-1-piperazinyl)methyl]phenyl}-2-pyridinecarbohydrazide 

Relevant articles and documents

Pyrazole Agonist of the Apelin Receptor Improves Symptoms of Metabolic Syndrome in Mice

Apelin receptor agonism improves symptoms of metabolic syndrome. However, endogenous apelin peptides have short half-lives, making their utility as potential drugs limited. Previously, we had identified a novel pyrazole-based agonist scaffold. Systematic modification of this scaffold was performed to produce compounds with improved ADME properties. Compound 13 with favorable agonist potency (cAMPi EC50 = 162 nM), human liver microsome stability (T1/2 = 62 min), and pharmacokinetic profile in rodents was identified. The compound was tested in a mouse model of diet-induced obesity (DIO) and metabolic syndrome for efficacy. Treatment with 13 led to significant weight loss, hypophagia, improved glucose utilization, reduced liver steatosis, and improvement of disease-associated biomarkers. In conclusion, a small-molecule agonist of the apelin receptor has been identified that is suitable for in vivo investigation of the apelinergic system in DIO and perhaps other diseases where this receptor has been implicated to play a role.

Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators

The present study describes the discovery and characterization of a series of 5-aryl-2H-tetrazol-3-ylacetamides as G protein-gated inwardly-rectifying potassium (GIRK) channels activators. Working from an initial hit discovered during a high-throughput screening campaign, we identified a tetrazole scaffold that shifts away from the previously reported urea-based scaffolds while remaining effective GIRK1/2 channel activators. In addition, we evaluated the compounds in Tier 1 DMPK assays and have identified a (3-methyl-1H-pyrazol-1-yl)tetrahydrothiophene-1,1-dioxide head group that imparts interesting and unexpected microsomal stability compared to previously-reported pyrazole head groups.

PROTEIN KINASE INHIBITORS

The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.